XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Agreements With, and Other Related Party Transactions: (Details)
12 Months Ended
May 22, 2023
patent
item
Feb. 29, 2024
USD ($)
item
Feb. 28, 2023
USD ($)
Agreements With, and Other Related Party Transactions      
Capital contributed | $   $ 524,156 $ 247,068
Clinical trial costs paid directly by Dr. Burzynski | $   $ 799,879 654,291
License Agreement | United States      
Agreements With, and Other Related Party Transactions      
Number of patents issued on which exclusive rights are owned   8  
License Agreement | Canada      
Agreements With, and Other Related Party Transactions      
Number of patents issued on which exclusive rights are owned   4  
License Agreement | Mexico      
Agreements With, and Other Related Party Transactions      
Number of patents issued on which exclusive rights are owned   1  
New License Agreement | United States      
Agreements With, and Other Related Party Transactions      
Number of patents issued on which exclusive rights are owned 4    
Number of pending patent applications | patent 1    
New License Agreement | Canada      
Agreements With, and Other Related Party Transactions      
Number of pending patent applications | patent 2    
Dr. Burzynski      
Agreements With, and Other Related Party Transactions      
Capital contributed | $   $ 524,156 247,068
Clinical trial costs paid directly by Dr. Burzynski | $   $ 799,879 $ 654,291
Dr. Burzynski | License Agreement      
Agreements With, and Other Related Party Transactions      
Number of other countries in which Patent Offices and Patent Officers issued patents   34  
Dr. Burzynski | Research Funding Agreement      
Agreements With, and Other Related Party Transactions      
Number of parties   2  
Renewable term   1 year  
Dr. Burzynski | Research Funding Agreement | Minimum      
Agreements With, and Other Related Party Transactions      
Notice period for nonrenewal prior to expiration of term of agreement   30 days  
Dr. Burzynski | Research Funding Agreement | Maximum      
Agreements With, and Other Related Party Transactions      
Net proceeds of any stock offering or private placement | $   $ 1,000,000  
Ownership percentage for termination of agreement   50.00%  
Dr. Burzynski | Royalty Agreement      
Agreements With, and Other Related Party Transactions      
Royalty interest as a percentage of gross income   10.00%  
Number of patients to be treated with antineoplaston products in option two, percentage added to cost of production to determine overall price   10.00%  
Dr. Burzynski | Royalty Agreement | Maximum      
Agreements With, and Other Related Party Transactions      
Number of patients to be treated with antineoplaston products under the option in which related party would have the right to produce the products without paying any fees   1,000  
Number of patients to be treated with antineoplaston products under the option in which related party would have the right to purchase the products from the company at specified price   1,000